Group 1: Fixed Income and Banking - The 2026 bond market is expected to perform better than anticipated, with a projected net issuance of around 20 trillion yuan, maintaining the same level as the previous year, and an increase in bank proprietary bond investments expected to reach 16 trillion yuan [2][8] - The anticipated policy interest rate cut of 10-20 basis points in 2026 is expected to lead to a corresponding decline in the Loan Prime Rate (LPR), with the 10Y government bond yield projected to fluctuate between 1.6% and 1.9% [2][8] - The credit investment strategy for March 2026 suggests a preference for medium-term duration strategies, with the M2 bank perpetual bonds showing significant outperformance compared to other bonds [9][10] Group 2: Media Industry - MiLian Technology has shown rapid revenue growth, with revenues increasing from 10.52 million yuan in 2022 to 19.17 million yuan in the first half of 2025, and a significant increase in average monthly active users by 45.81% year-on-year [14][15] - The company has expanded its application matrix, launching overseas market applications in 2024, which contributes to its growth potential in the online emotional market [14][15] - The platform fosters a vibrant user community through various interactive modes led by host users, enhancing user engagement and retention [15][16] Group 3: Pharmaceutical Industry - Yuan Dong Bio's revenue has grown from 162 million yuan in 2013 to 1.35 billion yuan in 2024, with a compound annual growth rate of 21.3%, driven by its anesthetic products and the strategic acquisition of Super Yang Pharmaceutical [18][19] - The company is focusing on innovative drug development, particularly in the CRBN molecular glue space, with its core product HP-001 showing Best-in-Class potential [18][19] - The internationalization of its anesthetic products is expected to contribute to revenue growth, with overseas sales increasing from 0.02 million yuan in 2017 to 0.25 million yuan in 2024 [20][21]

摘要 PROTAC 与分子胶技术进入商业化元年，Arvinas 的 ARV-471 与 BMS 的 Iberdomide 预计 2026 年获批，标志技术从概念转向产品落地。 AI 制药驱动研发范式由偶然发现转向理性设计，AlphaFold3 等工具提 升三元复合物预测精度，显著加速分子胶等候选药物产出。 新一代降解剂效率突破 95%阈值，KT-621 等产品实现"口服版小核 酸"性能，在自免等领域展现出替代注射用生物制剂的潜力。 百济神州 BTK PROTAC 在四线治疗中 ORR 达 94%，疗效优于 Nurix 同类产品，需关注 2026 年底二期单臂数据及房颤等安全性风险。 BMS 新一代分子胶结合力提升 20 倍，Mezigdomide 在末线 MM 患者 中 ORR 达 70%-80%，为苑东生物等后续竞争者留出安全性改良空间。 产业趋势由肿瘤耐药靶点向"不可成药"及自免领域拓展，LyTACs 等 新技术平台开始布局占人体蛋白 40%的胞外及膜蛋白降解。 Q&A 2026 年蛋白质降解领域有哪些值得关注的里程碑事件，以及该技术路线相较 于传统药物有何独特优势？ 2026 年蛋白质降解领域将迎来两个 ...

证券研究报告 医药生物 | 化学制药 非金融|公司深度报告 hyzqdatemark 2026 年 03 月 18 日 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 市场表现： | 基本数据 | | | 年 | 03 | 月 18 | 2026 | 日 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | | | 62.02 | | 一 年 内 最 低 | 高 | / | | | | | | | | （元） | | | | | | | | | | 总市值（百万元） | | | | | | | | 10,948.53 | | 流通市值（百万元） | | | | | | | | 10,948.53 | | 总股本（百万股） | | | | | | | | | | 资产负债率（%） | | | | | | | | 19.47 | | 每股净资产（元/股） | | | | | | | | 16.23 | | 资料来源：聚源数据 | | | | | | | | ...

Group 1 - The report highlights a shift in China's innovative drug development from "fast-following" to "innovation-leading," potentially reshaping the global new drug development landscape. Key emerging technology platforms include molecular glue, small nucleic acids, and in vivo CAR-T, with Chinese companies making significant investments in these areas [3][4]. - Molecular glue offers a new paradigm for targeting "undruggable" targets, with significant potential in the PAN-RAS space. Companies to watch include Heng Rui Medicine, Jinfang Medicine, Yuandong Biology, and Betta Pharmaceuticals [3]. - Small nucleic acids are expanding from rare diseases to chronic conditions, with numerous companies involved in hypertension, dyslipidemia, weight loss, MASH, and CNS diseases. Notable companies include Heng Rui Medicine, Shiyao Group, and Innovent Biologics [3]. - In vivo CAR-T technology is cost-effective and enhances accessibility, showing promise in oncology and autoimmune diseases. Key players include Yunding Xinyao and Kexi Pharmaceuticals [3]. - The integration of AI in healthcare and drug development is accelerating, with companies like Runda Medical and Kangzhong Medical leading the way [3]. Group 2 - The report reviews the performance of the pharmaceutical sector in 2025, noting a cumulative increase of 11.9% in the pharmaceutical index, while the broader market rose by 30.2%, indicating a relative underperformance of 18.3% [8][14]. - The valuation of the pharmaceutical sector has slightly improved, with the PE (TTM) ratio rising from 29.8x at the beginning of 2025 to 36.2x by year-end, while the broader market's PE increased from 28.6x to 39.5x [14]. - The pharmaceutical sector's revenue for the first three quarters of 2025 reached CNY 18,544 billion, with a year-on-year decline of 0.4%, and net profit attributable to shareholders was CNY 1,407 billion, down 0.8% year-on-year [17][22]. Group 3 - The report indicates that the number of IND (Investigational New Drug) applications for innovative drugs in 2025 reached 3,626, marking a year-on-year growth of 10.4%. The number of NDA (New Drug Application) submissions also increased, with 83 for chemical drugs and 271 for therapeutic biological products [31][29]. - The report emphasizes the growing trend of molecular glue technology, particularly in targeting RAS mutations, which are prevalent in approximately 30% of malignancies. The representative drug Daraxonrasib has shown significant clinical efficacy [53][50]. - The report notes an increase in collaboration and licensing activities in the molecular glue sector, with major pharmaceutical companies engaging in high-value transactions, indicating a robust interest in this innovative technology [54][56].

Investment Rating - The report suggests a positive investment outlook for the targeted protein degradation (TPD) industry, indicating it is at a historical turning point for commercialization, with significant growth potential similar to the ADC sector [1]. Core Insights - The TPD field is transitioning from a scientific concept to a commercial explosion, with key catalysts expected in 2026, including the approval of Arvinas' ARV-471 and BMS's Iberdomide, marking the realization of TPD technology's value after over 20 years of development [1]. - The report highlights the dual-driven technological landscape of PROTAC and molecular glue, with rapid penetration into new therapeutic areas such as autoimmune diseases, showcasing the industry's adaptability and growth potential [2]. - The emergence of AI technologies is accelerating the drug development process in TPD, making this an optimal time for investment as the first PROTAC molecules are set to commercialize [17]. Summary by Sections Investment Logic - TPD is expected to replicate the growth trajectory of ADCs, overcoming barriers associated with traditional small molecule inhibitors by utilizing the UPS and ALPS systems for effective protein degradation [1]. - 2026 is projected to be a pivotal year for commercialization, with significant drug approvals anticipated [1]. Technological Pathways - The report outlines a dual-driven approach with PROTAC and molecular glue technologies, emphasizing their clinical validation and the potential for new therapeutic applications [2]. - The self-immune field is highlighted as a strategic growth area, with companies like Kymera and Monte Rosa developing promising candidates [2]. Competitive Landscape - Key catalysts in 2026 are expected to reshape the competitive landscape, with companies demonstrating platform capabilities and differentiated target strategies likely to enjoy valuation premiums [3]. - The report identifies several leading companies and their promising pipelines, including Arvinas, Nurix, and Monte Rosa, which are positioned to capitalize on upcoming clinical data and market opportunities [3]. Investment Recommendations - The report recommends focusing on late-stage assets nearing commercialization, particularly those from Arvinas and BMS, while also highlighting biotech firms like Monte Rosa and Kymera that are expanding into autoimmune and chronic disease markets [4].

Investment Rating - The industry investment rating is "Buy" [1] Core Insights - The report highlights the rapid growth of synthetic biology, with a significant increase in the number of synthetic biology companies in Beijing's Changping District, which has surged nearly 70% compared to the same period last year, reaching a total of 146 companies [9] - The establishment of the world's largest pilot transformation platform by Huaxi Biological in Tianjin, which has a total investment of several billion yuan and spans 40,000 square meters, is a key development in the industry [10] - The National Development and Reform Commission has issued the "14th Five-Year Plan for the Development of the Bioeconomy," indicating a trillion-yuan market potential in the bioeconomy sector [4] Market Dynamics - The Huaxi Synthetic Biology Index decreased by 0.49% to 1271.82 during the week of February 24-27, 2026, underperforming compared to the Shanghai Composite Index, which rose by 1.98% [5] - The report notes that the synthetic biology sector is experiencing a wave of technological advancements and increased investment, with nearly 100 companies completing new financing rounds since 2025 [33] Company Developments - Huaxi Biological's pilot platform has already undertaken over 30 biological manufacturing projects, facilitating the transition from laboratory-scale to commercial-scale production [10] - The report mentions that Lif Biological's PEF (polyethylene furanoate) has received approval for food contact use, marking a significant step for bio-based materials in the food packaging sector [24] - Watson Biological has announced a 450 million yuan investment to establish a fund focused on synthetic biology, with a target size of 1 billion yuan [25] Industry Financing - The report indicates that financing in the synthetic biology sector is accelerating, with companies like Rhein Biological and EcoviaBio completing multiple rounds of financing to expand their production capabilities [33][34] - Rhein Biological is focusing on two main development directions: enhancing its core business and providing industrialization services for external synthetic biology products [34]

Investment Rating - The industry investment rating is "Buy" [1] Core Insights - The report highlights the rapid growth of synthetic biology, with a significant increase in the number of synthetic biology companies in Beijing's Changping District, which has surged nearly 70% compared to the same period last year, reaching a total of 146 companies [9] - The establishment of the world's largest pilot transformation platform by Huaxi Biological in Tianjin, which has a total investment of several billion yuan and spans 40,000 square meters, is a key development in the industry [10] - The "14th Five-Year Plan" for the development of the bio-economy has been issued by the National Development and Reform Commission, indicating a trillion-yuan market potential in the bio-economy sector [4] Market Dynamics - The Huaxi Synthetic Biology Index decreased by 0.49% to 1271.82 during the week of February 24-27, 2026, underperforming compared to the Shanghai Composite Index, which rose by 1.98% [5] - The report notes that the synthetic biology sector is experiencing a biotechnology revolution, providing innovative solutions to major challenges such as health, climate change, and food security [4] Company Developments - The report mentions that Watson Bio has established a 450 million yuan industry fund focused on synthetic biology, with a target size of 1 billion yuan [25] - Jin Dan Technology announced an additional investment of approximately 148 million yuan in its 75,000-ton annual production project for polylactic acid, bringing the total investment to 1.03 billion yuan [26] - The report also highlights the successful commercialization of products such as mannitol and alonose by companies like Weiyuan Synthetic [9] Industry Financing - The report indicates that financing in the synthetic biology sector is accelerating, with nearly 100 companies completing new financing rounds since 2025 [33] - EcoviaBio completed a Series B financing round to expand its production capacity for gamma-polyglutamic acid, a biodegradable material [34] - Verley, a precision fermentation company, successfully completed a $38 million Series A financing, marking a significant step towards commercializing precision fermentation [34]

【华创医药】苑东生物2025业绩快报点评：利润表现亮眼，看好26年精麻主业放量以及上海超阳平台价值的兑现 2025年公司营业收入13.31亿元（-1.36%)，归母净利润2.83亿元（+18.89%），扣非净利润2.06亿元（+18.01%）， 其中单Q4营业收入3.12亿元（+0.8%），归母净利润0.63亿元（+197.2%），扣非净利润0.33亿元（+376.9%）。 同时若还原股权激励费用，预计公司 利润端，2025年公司积极推动研发体系整合，对仿制药以及部分在研创新药进行成本管控，尽管上海超阳25H2并 表后确认了额外研发费用，但我们预计公司整体研发费用率仍实现了优化，这一趋势我们认为在2026年还将延 续。 2026年管制精麻核心产品放量有望带动业绩维持稳健增长 2026年公司管制精麻管线放量持续加速，预计收入体量将从2025年6000+万元提升至2亿元以上（主要由纳布啡、 布托啡诺、麻黄碱、奥沙西泮贡献），同时氨酚羟考酮、吗啡纳曲酮获批在即，届时将参加年内医保谈判，我们 预计苑东26年仍有望实现20%利润增速。 上海超阳研发进展顺利，平台价值想象空间巨大 1）HP-001（IKZF1/3分子胶） ...

成都苑东生物制药股份有限公司2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 证券代码：688513 证券简称：苑东生物 公告编号：2026-005 报告期内，公司实现营业总收入133,139.76万元，同比减少1.36%；实现归属于母公司所有者的净利润 28,324.83万元，同比增长18.89%；实现归属于母公司所有者的扣除非经常性损益的净利润20,624.39万 元，同比增长18.01%。 报告期末公司总资产379,885.73万元，较报告期初增长11.73%，归属于母公司的所有者权益293,202.71 万元，较报告期初增长8.68%。 本公告所载成都苑东生物制药股份有限公司（以下简称"公司"）2025年度主要财务数据为初步核算数 据，未经会计师事务所审计，具体数据以公司2025年年度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：万元 ■ 注：1、本报告期初数同法定披露的上年年末数。 2、以上财务数据及指标以合并报表数据填制，但未经审计，最终结果以公司2025 ...

Core Viewpoint - Yuan Dong Biotech (688513.SH) reported a slight decrease in total revenue for the fiscal year 2025, but achieved a significant increase in net profit, indicating effective management strategies in response to market challenges [1] Financial Performance - The company achieved total revenue of 1.331 billion yuan, a year-on-year decrease of 1.36% [1] - The net profit attributable to the parent company was 283 million yuan, reflecting a year-on-year increase of 18.89% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 206 million yuan, with a year-on-year growth of 18.01% [1] Operational Strategies - The slight decline in total revenue was influenced by the implementation of the tenth batch of national centralized procurement [1] - The company adopted multiple measures, including optimizing revenue structure, enhancing cost control, and improving operational efficiency, to mitigate the adverse effects of the procurement policy [1] - There was an increase in revenue from technical services and transfers, alongside a reduction in costs and expenses, contributing to stable profit growth [1]